Filter Results:
(1,317)
Show Results For
- All HBS Web
(1,317)
- People (2)
- News (339)
- Research (765)
- Events (2)
- Multimedia (5)
- Faculty Publications (389)
Show Results For
- All HBS Web
(1,317)
- People (2)
- News (339)
- Research (765)
- Events (2)
- Multimedia (5)
- Faculty Publications (389)
- 22 Apr 2016
- HBS Seminar
Dr. Milt McColl, MD, Gauss Surgical, CEO
- Web
Class Profile - Doctoral
Pricing Corporate Governance Corporate Strategy Corporate Finance Diversity Emerging Markets Environment Ethics Experimental Economics Game Theory View Details
- January 2017 (Revised October 2018)
- Case
Novartis: A Transformative Deal
By: David Collis and Ashley Hartman
When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and... View Details
Keywords: Novartis; GlaxoSmithKline; Asset Swap; Acquisitions; Divestiture; Strategy Alignment; Pharmaceuticals; Strategy; Business Strategy; Corporate Strategy; Diversification; Consolidation; Mergers and Acquisitions; Pharmaceutical Industry
Collis, David, and Ashley Hartman. "Novartis: A Transformative Deal." Harvard Business School Case 717-453, January 2017. (Revised October 2018.)
- 2020
- Working Paper
Venture Capitalists and COVID-19
By: Paul A. Gompers, Will Gornall, Steven N. Kaplan and Ilya A. Strebulaev
We survey over 1,000 institutional and corporate venture capitalists (VCs) at more than 900 different firms to learn how their decisions and investments have been affected by the COVID-19 pandemic. We compare their survey answers to those provided by a large sample of... View Details
Gompers, Paul A., Will Gornall, Steven N. Kaplan, and Ilya A. Strebulaev. "Venture Capitalists and COVID-19." NBER Working Paper Series, No. 27824, September 2020.
- November 2021
- Article
Venture Capitalists and COVID-19
By: Paul A. Gompers, Will Gornall, Steven N. Kaplan and Ilya A. Strebulaev
We survey over 1,000 institutional and corporate venture capitalists (VCs) at more than 900 different firms to learn how their decisions and investments have been affected by the COVID-19 pandemic. We compare their survey answers to those provided by a large sample of... View Details
Keywords: Investment Decisions; COVID-19 Pandemic; Impact; Health Pandemics; Venture Capital; Investment; Decision Making; Surveys
Gompers, Paul A., Will Gornall, Steven N. Kaplan, and Ilya A. Strebulaev. "Venture Capitalists and COVID-19." Journal of Financial and Quantitative Analysis 56, no. 7 (November 2021).
- Program
Audit Committees in a New Era of Governance
Summary As the focus on corporate governance and oversight has grown, so has the complexity of regulatory challenges facing audit committees. This corporate governance strategy program explores the best... View Details
- Web
Accounting & Management - Faculty & Research
address healthcare inequities in the U.S., disparities across race, gender, geography, and income remain stubbornly persistent. This article introduces the Strategic Fingerprint Framework for Health Equity, a practical, principle-based... View Details
- Program
PLD Module 5
company build and sustain a competitive advantage. You will emerge with the leadership skills and confidence to make high-level decisions that support your organization's financial needs, legal requirements, ethical obligations, and View Details
Gerald Zaltman
*Joined Harvard Faculty: 1991
Prior Faculty Appointments: Northwestern University, 1968-75;
University of Pittsburgh, 1975-91
Prior Faculty Appointments: Northwestern University, 1968-75;
University of Pittsburgh, 1975-91
*Doctoral Degree in Sociology Received from: The John Hopkins University;
MBA Degree Received from: The University of... View Details
F. Warren McFarlan
Professor McFarlan earned his AB from Harvard University in 1959, and his MBA and DBA from the Harvard Business School in 1961 and 1965 respectively. He has had a significant role in introducing materials on Management Information Systems to all major programs at... View Details
- 17 Oct 2006
- First Look
First Look: October 17, 2006
across their internal corporate departments lead their facilities to prioritize different institutional pressures and thus adopt different management practices. Specifically, we argue that external constituents who interact with... View Details
Keywords: Sean Silverthorne
- Web
Research Areas - Doctoral
faculty-designed research project based on their indicated interests. 1. Corporate Social Responsibility research explores business impact of delivering economic, social, and environmental benefits to stakeholders. 2. Business and... View Details
- 18 Sep 2013
- News
The 10 most influential women in biotech
- Program
Compensation Committees
Corporate Director Certificate. Learn More Key Benefits This executive compensation training program will enable you and your committee to contribute more effectively to long-term performance, corporate... View Details
- August 2009
- Case
Intel NBI: Vivonic
By: Willy C. Shih and Thomas Thurston
Vivonic was a start-up that was part of Intel's New Business Initiatives that sought to develop and sell personal health monitoring hardware and software. When it was first funded, Intel was in the midst of record growth and was seeking diversification. But the company... View Details
Keywords: Business Startups; Experience and Expertise; Corporate Entrepreneurship; Product Development; Failure; Diversification; Semiconductor Industry
Shih, Willy C., and Thomas Thurston. "Intel NBI: Vivonic." Harvard Business School Case 610-025, August 2009.
- March 2022 (Revised March 2024)
- Case
DaVita Responds to COVID
By: Susanna Gallani and David Lane
Early in August 2021, DaVita CEO Javier Rodriguez was assessing the ongoing impact of the COVID-19 pandemic on his firm, which provided life-sustaining kidney dialysis to roughly 240,000 people. Effective infection control practices and information sharing had ensured... View Details
Keywords: COVID-19 Pandemic; Change Management; Communication; Talent and Talent Management; Fairness; Values and Beliefs; Corporate Accountability; Health Care and Treatment; Health Pandemics; Human Resources; Employee Relationship Management; Retention; Wages; Working Conditions; Leadership Style; Crisis Management; Organizational Culture; Health Industry; United States
Gallani, Susanna, and David Lane. "DaVita Responds to COVID." Harvard Business School Case 122-007, March 2022. (Revised March 2024.)
- January 2023
- Teaching Note
The Opioid Settlement and Executive Pay at AmerisourceBergen
By: Suraj Srinivasan and Li-Kuan Ni
Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged... View Details
Keywords: Opioids; Shareholder Activism; Investment Activism; Corporate Accountability; Corporate Governance; Governance Compliance; Governance Controls; Executive Compensation; Risk Management; Corporate Social Responsibility and Impact; Business and Shareholder Relations; Business and Stakeholder Relations; Health Industry; Health Industry; Health Industry; United States; West Virginia; Tennessee; Ohio; Pennsylvania
- Program
Senior Executive Leadership Program—China
to corporate success on a more strategic and senior level. Gain a new ability to think strategically, seize growth opportunities, and compete successfully both within the region and globally Foster the innovations that will improve your... View Details
- Web
Technology & Operations Management - Faculty & Research
compliance with multinational enterprises’ (MNEs’) labor standards. Analyzing audit data from thousands of Chinese suppliers, we find that suppliers in cities with more wage-related activism increased compliance with MNEs’ wage-related standards but tempered... View Details
- Web
Podcast - Business & Environment
credits are verified and rated. The conversation also highlights key themes in the voluntary carbon market, including the tension between financial models and credibility, the challenges of measuring impact, and the broader implications for View Details